Vantage Isotopes
Vantage Isotopes Revenue Share
A share of metered output from an operating actinium-225 and molybdenum-99 production line.
Actinium-225 is one of the scarcest useful substances on earth and targeted alpha therapy demand is growing faster than supply. Vantage operates an accelerator-driven subcritical target that has been shipping for two years under three take-or-pay distribution agreements. Investors receive 4% of gross isotope revenue until a 1.9x cap, paid quarterly against metered output.
$5,000,000 committed of $5,000,000
$5,000,000 released · 100% subscribed
- Minimum
- $100
- Instrument
- Revenue share
- Term
- 10 yr
- Investors
- 2,766
$50 per unit
Closed April 30, 2026
Sign in to see your limit
- Eligibility depends on residency, accreditation status and how much you have already invested this year.
- You can read everything about this offering without an account. Committing capital requires one.
Demo · viewing as
Browsing without an account. Everything is visible; nothing is purchasable until you verify who and where you are.
Or answer the questions yourselfNo money will move
No payment processor is connected. The commitment flow runs end to end, through amount, agreement, signature and receipt, and records a simulated position rather than a charge.
Capital release schedule
1 of 1 rungs released
Release is structured as staged closings rather than withheld proceeds. Amounts shown are cumulative against the $5M committed to this offering.
Commercial operation sustained, twelve months
Capital released- TRL target
- TRL 9
- Cumulative release
- 100% · $5,000,000
- Certified
- May 2, 2026
Verified by: Metered output records; distributor acceptance
Certifier: Cordell Independent Verification
Held by the escrow agent on subscription
100% of committed capital
Unlocks on the next certification
Escrow agent: Cadence Escrow Services. Certification is performed by an independent party with no economic interest in the release.